Engineering of Humanized PSMA-Directed CAR T Cells for Potent and Specific Elimination of Prostate Cancer Cells
Cells · 2025
DOI: 10.3390/cells14171333 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Tobias D Deller und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Transfusion Medicine and Gene Therapy, Medical Center-University of Freiburg, 79106 Freiburg, Germany. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Receptors, Chimeric Antigen, Glutamate Carboxypeptidase II, Immunotherapy, Adoptive. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Freiburg, Mildred-Scheel-Doktorandenprogramm, German Cancer Aid, German Federal Ministry of Economic Affairs and Energy.
Abstract (Originalsprache)
Chimeric Antigen Receptor (CAR) T cell therapy has achieved high response rates in patients with relapsed or refractory hematologic malignancies. However, comparable efficacy in solid tumors remains limited, partly due to poor CAR T cell persistence and immune-mediated rejection. A major contributor, which has hampered the clinical efficacy of CAR T cells in clinical practice, is the immunogenicity of the murine-derived single-chain variable fragments (scFvs) commonly used in CAR constructs. Cell and humoral immune responses to the murine parts of CARs have been implicated in CAR T cell rejection. Here, we describe the generation and in vitro characterization of humanized CAR T cells targeting prostate-specific membrane antigen (PSMA) on prostate cancer cells, based on two distinct murine scFvs (A5 and D7). Humanization improved the germinality index and successfully preserved CAR surface expression. Functional assays demonstrated that humanized PSMA-CAR T cells retained antigen-specific binding, activation and cytotoxicity, differentiation, exhaustion and cytokine secretion profiles comparable to their murine counterparts. These results support the feasibility of humanization as a strategy to reduce immunogenicity without compromising CAR T cell capabilities, providing a foundation for further in vivo validation in solid tumor settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Transfusion Medicine and Gene Therapy, Medical Center-University of Freiburg, 79106 Freiburg, Germany.
- Center for Cell and Gene Therapy, Medical Center-University of Freiburg, 79106 Freiburg, Germany.
- Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.
- Department of Haematooncology, Faculty of Medicine, University of Ostrava, 70852 Ostrava, Czech Republic.
- Department of Urology, Medical Center-University of Freiburg, 79106 Freiburg, Germany.
- Faculty of Biology, University of Freiburg, 79104 Freiburg, Germany.
ORCID-Profile: Jamal Alzubi, Laura Mosti, Marie Peschers, Philipp Wolf, Toni Cathomen
Förderung
- University of Freiburg
- Mildred-Scheel-Doktorandenprogramm, German Cancer Aid
- German Federal Ministry of Economic Affairs and Energy
- German Research Foundation
- German Cancer Aid
- Ministry of Health of the Czech Republic
- Medical Faculty, University of Freiburg
- Open Access Publication Fund of the University of Freiburg
Zitieren
APA
Deller, T. D., Alzubi, J., Mosti, L., Peschers, M., Gratzke, C., Wolf, P., & Cathomen, T. (2025). Engineering of Humanized PSMA-Directed CAR T Cells for Potent and Specific Elimination of Prostate Cancer Cells. Cells. https://doi.org/10.3390/cells14171333
Vancouver
Deller TD, Alzubi J, Mosti L, Peschers M, Gratzke C, Wolf P, et al. Engineering of Humanized PSMA-Directed CAR T Cells for Potent and Specific Elimination of Prostate Cancer Cells. Cells. 2025. doi:10.3390/cells14171333
BibTeX
@article{Deller2025,
author = {Deller, Tobias D and Alzubi, Jamal and Mosti, Laura and Peschers, Marie and Gratzke, Christian and Wolf, Philipp and Cathomen, Toni},
title = {Engineering of Humanized PSMA-Directed CAR T Cells for Potent and Specific Elimination of Prostate Cancer Cells},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14171333}
}
EUVIMED